RVNC - Revance to file U.S. application for DAXI for frown lines in late Q3 May, 08 2019 04:35 PM Revance Therapeutics Inc. Revance Therapeutics (NASDAQ:RVNC) announces Q1 results. Highlights: Revenue: $278K; net loss: ($35.3M).More news on: Revance Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...